{"schemaVersion":"cwiki-fiche-1.0","identifiers":{"inchiKey":"YRDNBEPFVBMTNP-CLJLJLNGSA-N","prefName":"O-1057","symbol":"O-1057","iupacName":"[(6aR,10aR)-3-(6-cyano-2-methylhexan-2-yl)-6,6,9-trimethyl-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-yl] 4-morpholin-4-ylbutanoate","aliases":["O-1057 free base"],"cas":null,"pubchemCid":"9829239","chebiId":null,"smiles":"CC1=CC[C@@H]2[C@@H](C1)c1c(OC(=O)CCCN3CCOCC3)cc(C(C)(C)CCCCC#N)cc1OC2(C)C","molecularFormula":"C32H46N2O4","molecularWeight":522.7,"xrefs":{"pubchem":"https://pubchem.ncbi.nlm.nih.gov/compound/9829239"}},"classification":{"family":"scra","familyLabel":"Synthetic cannabinoid (SCRA)","origin":"synthetic","originLabel":"Synthétique","structuralClassFr":null},"originSynthesis":{"heading":"Origin (pharmaceutical research → illicit market)","summaryFr":"No biosynthetic pathway: the molecule is obtained by organic synthesis and belongs to the class of water-soluble amino esters of tetrahydrocannabinols, used as the hydrochloride salt.","originNote":"Synthetic molecule, with no plant species recorded in the reference data. It was described as a new water-soluble cannabinoid, studied in cells and rodents, and the sources consulted do not report it in any food or cosmetic product.","discovered":""},"pharmacology":{"summaryFr":"O-1057 is an amino ester of Δ8-tetrahydrocannabinol, designed to be more potent than Δ9-tetrahydrocannabinol and to dissolve in water. Classical cannabinoids dissolve poorly in water and require a solubilising agent that may itself have pharmacological activity; esterifying the phenol at position 1 with 4-morpholinobutyric acid, used as the hydrochloride salt, yields a compound soluble in water or in saline solution. On membranes of CHO cells expressing the CB1 and CB2 receptors, its pKi is 8.36 for CB1 and 7.95 for CB2, that is, affinities in the nanomolar range, and it inhibits cyclic AMP with a pEC50 of 9.16 and 9.72 (Pertwee et al., 2000). In mice, intravenous injection reduces spontaneous activity, lowers rectal temperature and produces antinociception with an ED50 of 0.02 mg/kg, an effect that SR 141716A blocks. In rats, the agonist is self-administered into the shell of the nucleus accumbens, and rats selected for their preference for alcohol self-administer it at lower concentrations and at a higher rate than Wistar rats (Hauser et al., 2020). The authors judge its clinical potential as an analgesic worth investigating, but no human data are published: no pharmacokinetics, no characterised metabolism, no clinical trial, no safety profile.","receptorSummaryFr":"Agonist at the CB1 and CB2 receptors, without marked selectivity between the two: the authors report that the pKi values do not differ significantly. On membranes of CHO cells expressing CB1 or CB2, the compound displaces radiolabelled CP55940 with a pKi of 8.36 for CB1 and 7.95 for CB2, that is, affinities in the nanomolar range; on rat brain membranes, the pKi is 7.86. It inhibits forskolin-stimulated cyclic AMP with a pEC50 of 9.16 at CB1 and 9.72 at CB2, a potency the authors judge equal to that of CP55940 and greater than that of Δ9-tetrahydrocannabinol. In the isolated mouse vas deferens, it inhibits electrically evoked contractions, with a pEC50 of 9.73 and a maximal effect of 76.84 %, an effect antagonised by SR 141716A (pKB of 8.90, against 8.97 for CP55940). The sources consulted report no measurement at other targets.","binding":[{"target":"CB1","efficacy":"full_agonist","relativeActivity":89,"reported":"pKi 8,36 sur membranes de cellules CHO exprimant CB1 ; pEC50 de 9,16 pour l'inhibition de l'AMP cyclique (Pertwee et coll., 2000)","confidence":"medium"},{"target":"CB2","efficacy":"full_agonist","relativeActivity":84,"reported":"pKi 7,95 sur membranes de cellules CHO exprimant CB2 ; pEC50 de 9,72 pour l'inhibition de l'AMP cyclique (Pertwee et coll., 2000)","confidence":"medium"},{"target":"Récepteurs cannabinoïdes du cerveau de rat","efficacy":"full_agonist","relativeActivity":82,"reported":"pKi 7,86 sur membranes de cerveau de rat (Pertwee et coll., 2000)","confidence":"medium"},{"target":"Canal déférent de souris (récepteurs cannabinoïdes)","efficacy":"full_agonist","relativeActivity":92,"reported":"pEC50 9,73 sur les contractions évoquées électriquement, effet maximal 76,84 % ; antagonisé par le SR 141716A (pKB 8,90, contre 8,97 pour le CP55940) (Pertwee et coll., 2000)","confidence":"medium"}],"references":[{"label":"Pertwee et coll., O-1057, un agoniste cannabinoïde hydrosoluble puissant aux propriétés antinociceptives, Br J Pharmacol 2000","pmid":"10780961","doi":"10.1038/sj.bjp.0703245","url":"https://pubmed.ncbi.nlm.nih.gov/10780961/"},{"label":"Lichtman et coll., Évaluation pharmacologique de cannabinoïdes administrés en aérosol chez la souris, Eur J Pharmacol 2000","pmid":"10884513","doi":"10.1016/s0014-2999(00)00321-6","url":"https://pubmed.ncbi.nlm.nih.gov/10884513/"},{"label":"Martin et coll., Caractérisation pharmacologique de nouveaux cannabinoïdes hydrosolubles, J Pharmacol Exp Ther 2006","pmid":"16757541","doi":"10.1124/jpet.106.104109","url":"https://pubmed.ncbi.nlm.nih.gov/16757541/"},{"label":"Hauser et coll., Sélection pour la préférence pour l'alcool et sensibilité accrue au renforcement cannabinoïde dans la coquille du noyau accumbens, Pharmacol Biochem Behav 2020","pmid":"32710885","doi":"10.1016/j.pbb.2020.173002","url":"https://pubmed.ncbi.nlm.nih.gov/32710885/"},{"label":"PubChem, composé CID 9829239 (O-1057), National Library of Medicine","pmid":null,"doi":null,"url":"https://pubchem.ncbi.nlm.nih.gov/compound/9829239"},{"label":"ANSM, liste consolidée des substances classées comme stupéfiants, mise à jour du 16 février 2026 (clause du noyau benzo[c]chromène)","pmid":null,"doi":null,"url":"https://ansm.sante.fr/uploads/2026/02/17/20260217-stupefiants-liste-consolidee.pdf"},{"label":"ANSM, décision du 22 mai 2024 portant modification de la liste des substances classées comme stupéfiants","pmid":null,"doi":null,"url":"https://ansm.sante.fr/actualites/decision-du-22-05-2024-portant-modification-de-la-liste-des-substances-classees-comme-stupefiants"},{"label":"OICS, Liste verte 2026 des substances psychotropes sous contrôle international (convention de 1971)","pmid":null,"doi":null,"url":"https://www.incb.org/incb/uploads/documents/Psychotropics/forms/greenlist/2026/2510307E.pdf"}]},"pharmacokinetics":null,"metabolism":null,"detection":null,"subjectiveEffects":{"profile":[{"key":"calm","label":"Calm","description":"Relaxation of body and mind; reduced mental noise without marked drowsiness.","intensity":12},{"key":"focus","label":"Clarity","description":"Sustained attention and clear thinking; functional lucidity, not euphoria.","intensity":4},{"key":"sleep","label":"Sleep","description":"Sedative effect: aids sleep onset and the continuity of deep sleep.","intensity":10},{"key":"appetite","label":"Appetite","description":"Stimulation of hunger and of taste appreciation (the “munchies” effect).","intensity":8},{"key":"uplift","label":"High","description":"Euphoria and sensory intensity; altered perception of time and space.","intensity":6}],"doseRanges":null,"humanDataCharacterised":false},"indications":{"approvedMedicines":[]},"harmProfile":{"unstudiedBanner":true,"bannerTextFr":"Aucune dose humaine caractérisée : données animales / in vitro uniquement. Profil d'effet, marge de sécurité et toxicité aiguë non documentés en clinique humaine.","toxicologyFr":null},"legal":{"scheduleStatus":"unscheduled","scheduleLabel":"Unscheduled","frScheduleStatus":"controlled-clause","tiers":[{"jurisdiction":"international","jurisdictionLabel":"International","label":null,"reference":null,"url":null,"effectiveDate":null,"lastVerified":"2026-05-01","supersededBy":null},{"jurisdiction":"eu","jurisdictionLabel":"Union européenne","label":"No harmonised measure at European Union level has been found in the sources consulted: control therefore falls to national legislation. Internationally, the molecule is not named in the 2026 Green List of the International Narcotics Control Board, which lists isomers of tetrahydrocannabinol all bearing a pentyl chain at position 3 and a free hydroxyl at position 1, which O-1057 is not. No marketing authorisation and no clinical trial has been found in the sources consulted.","reference":null,"url":null,"effectiveDate":null,"lastVerified":"2026-05-01","supersededBy":null},{"jurisdiction":"fr","jurisdictionLabel":"France","label":"Narcotic status in France through a generic clause. O-1057 is named by its code in no annex of the ANSM consolidated list updated on 16 February 2026. Annex III does, however, name « tetrahydrocannabinols, their esters, ethers, salts and the salts of the aforementioned derivatives », and the text does not settle whether that entry extends to a molecule whose position-3 chain differs; this sheet therefore relies only on the clause. The clause covers any substance derived from the benzo[c]chromene nucleus, un-, partially or fully hydrogenated on ring A (the unsaturated ring bearing the methyl at position 9), and substituted at one of the places it lists; the list cites the decision of 22 May 2024 in the same entry. O-1057 meets each of its conditions. The skeleton is that of Δ8-tetrahydrocannabinol; the hydroxyl at position 1 is esterified, a case the clause expressly provides for; position 3 carries a cyanoalkyl chain itself substituted by two methyl groups, also provided for; position 6 carries two alkyl groups and position 9 a methyl. None of the clause's exceptions (cannabinol, cannabinolic acid, THCV, THCVA and THCA, under their conditions) applies. No marketing authorisation and no admission as a food or cosmetic ingredient has been found in the sources consulted, and the classification opens no right of use.","reference":null,"url":null,"effectiveDate":null,"lastVerified":"2026-05-01","supersededBy":null}],"sourcesFr":"EUR-Lex, UNODC, CND, ANSM, IUPHAR/BPS, ChEBI, EUDA."},"references":[{"label":"Pertwee et coll., O-1057, un agoniste cannabinoïde hydrosoluble puissant aux propriétés antinociceptives, Br J Pharmacol 2000","pmid":"10780961","doi":"10.1038/sj.bjp.0703245","url":"https://pubmed.ncbi.nlm.nih.gov/10780961/"},{"label":"Lichtman et coll., Évaluation pharmacologique de cannabinoïdes administrés en aérosol chez la souris, Eur J Pharmacol 2000","pmid":"10884513","doi":"10.1016/s0014-2999(00)00321-6","url":"https://pubmed.ncbi.nlm.nih.gov/10884513/"},{"label":"Martin et coll., Caractérisation pharmacologique de nouveaux cannabinoïdes hydrosolubles, J Pharmacol Exp Ther 2006","pmid":"16757541","doi":"10.1124/jpet.106.104109","url":"https://pubmed.ncbi.nlm.nih.gov/16757541/"},{"label":"Hauser et coll., Sélection pour la préférence pour l'alcool et sensibilité accrue au renforcement cannabinoïde dans la coquille du noyau accumbens, Pharmacol Biochem Behav 2020","pmid":"32710885","doi":"10.1016/j.pbb.2020.173002","url":"https://pubmed.ncbi.nlm.nih.gov/32710885/"},{"label":"PubChem, composé CID 9829239 (O-1057), National Library of Medicine","pmid":null,"doi":null,"url":"https://pubchem.ncbi.nlm.nih.gov/compound/9829239"},{"label":"ANSM, liste consolidée des substances classées comme stupéfiants, mise à jour du 16 février 2026 (clause du noyau benzo[c]chromène)","pmid":null,"doi":null,"url":"https://ansm.sante.fr/uploads/2026/02/17/20260217-stupefiants-liste-consolidee.pdf"},{"label":"ANSM, décision du 22 mai 2024 portant modification de la liste des substances classées comme stupéfiants","pmid":null,"doi":null,"url":"https://ansm.sante.fr/actualites/decision-du-22-05-2024-portant-modification-de-la-liste-des-substances-classees-comme-stupefiants"},{"label":"OICS, Liste verte 2026 des substances psychotropes sous contrôle international (convention de 1971)","pmid":null,"doi":null,"url":"https://www.incb.org/incb/uploads/documents/Psychotropics/forms/greenlist/2026/2510307E.pdf"}],"meta":{"slug":"o-1057","url":"https://en.phytogrammes.com/wiki/o-1057","lastVerified":"2026-05-01","dataUpdatedAt":"2026-10-12","confidence":"high","dataCompletenessPct":90,"disclaimerFr":"Contenu éditorial informatif, sans valeur d'avis médical ni juridique. Sources primaires citées par fiche. Réservé aux adultes."}}